# Teon Therapeutics, Inc.

> Teon Therapeutics is a clinical-stage, privately held biopharmaceutical company in Redwood City, California, developing a focused portfolio of orally administered small-molecule drugs that block immunosuppressive, cancer-promoting signaling pathways in the tumor microenvironment. Its GPCR-directed candidates - TT-702, a first-in-class adenosine A2B receptor antagonist, and TT-816, a first-in-class cannabinoid CB2 receptor antagonist - aim to restore anti-tumor immunity for the roughly 88% of solid-tumor patients who do not benefit from existing immunotherapies. The founding team members were primary inventors of Lexiscan, the only FDA-approved selective adenosine therapeutic.

- **Founded:** 2018
- **Headquarters:** Redwood City, California, United States
- **Founders:** Lina Yao (Founder, President & Interim CEO (also Chief Scientific Officer)), Peter Fan (Co-founder, SVP Head of Biology & Pharmacology), Elfatih Elzein (Co-founder, SVP Head of Chemistry & Early Development), Jim Liu (Co-founder)
- **Team size:** ~7 employees
- **Products:** TT-702, TT-816
- **Notable:** Advanced two first-in-class oral small molecules (TT-702 and TT-816) into Phase 1/2 clinical trials, Completed a $30 million Series A financing in February 2021 led by Oceanpine Capital, Founding team were primary inventors of Lexiscan, the only FDA-approved selective adenosine therapeutic, tied to Gilead's acquisition of CV Therapeutics

## Products & services

- **TT-702** — First-in-class, oral, once-daily adenosine A2B receptor antagonist in a Phase 1/2 trial for metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer (TNBC), and MSI/MMR-deficient cancers. First patient dosed in partnership with Cancer Research UK.
- **TT-816** — First-in-class oral cannabinoid CB2 receptor antagonist acting as a novel immune checkpoint inhibitor; promotes T-cell infiltration of cold tumors and NK-cell killing. Studied as monotherapy and in combination with Merck's KEYTRUDA (pembrolizumab) in NSCLC, ovarian cancer, and renal cell carcinoma.

## Achievements

- Advanced two first-in-class oral small molecules (TT-702 and TT-816) into Phase 1/2 clinical trials
- Completed a $30 million Series A financing in February 2021 led by Oceanpine Capital
- Founding team were primary inventors of Lexiscan, the only FDA-approved selective adenosine therapeutic, tied to Gilead's acquisition of CV Therapeutics
- Secured a clinical collaboration with Cancer Research UK to dose the first TT-702 patient
- Established a combination study of TT-816 with Merck's KEYTRUDA (SEABEAM / MK3475-E88)

## Latest updates

- **2021-02** — Completed $30M Series A financing led by Oceanpine Capital.
- **2021** — Initiated Phase 1/2 trial of TT-702, an adenosine A2B receptor antagonist.
- **2022-11** — Announced first patient treated in the Phase 1/2 trial of TT-816, an oral CB2 antagonist immune checkpoint inhibitor.
- **2022** — Cancer Research UK and Teon announced first patient dosed in the TT-702 Phase I/II trial for hard-to-treat solid cancers.

## Links

- Website: https://teontherapeutics.com
- LinkedIn: http://www.linkedin.com/company/teon-therapeutics-inc
- Twitter/X: https://twitter.com/TeonTx

---

Profile page: https://yespress.io/teon-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-17